Diabetes & Endocrinology Clinical Trials Update: Week 26, 2026

Published June 26, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

This Phase 3 trial is testing a new oral medication called orforglipron against dulaglutide injections in children aged 10 to under 18 with type 2 diabetes. If successful, this study could lead to a simpler treatment option by replacing weekly injections with a once-daily pill. This may make it easier for young patients to manage their diabetes and improve how well they stick to their treatment.

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

This Phase 4 study compares oral metformin to injectable insulin for pregnant people with gestational diabetes. The goal is to find out if metformin can be a safer and more convenient alternative that avoids the need for injections during pregnancy. The study will also follow mothers and their children for two years after birth to understand long-term effects.

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

This Phase 3 trial is evaluating elecoglipron, a new drug intended to help adults who are overweight or have obesity, with or without type 2 diabetes. If the drug works as hoped, it could provide a new option to reduce body weight alongside diet and exercise. The study plans to include 4500 participants from various countries.

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

This Phase 3 trial compares elecoglipron with oral semaglutide in adults with type 2 diabetes. The aim is to see if elecoglipron can better manage blood sugar and be safe for patients. The study expects to enroll 1200 participants worldwide to provide a broad understanding of the drug’s effects.

AMAZE 13: A Research Study Investigating How Well the Medicine Zenagamtide Helps People in Asia With Excess Body Weight Lose Weight

This Phase 3 study is testing zenagamtide, a once-weekly injection, in Asian adults who are overweight or obese. If effective, zenagamtide could offer a new treatment option with a convenient weekly dose to support weight loss. The study will recruit 400 participants in India and Japan to examine its safety and benefits.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.